Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,601,305 papers from all fields of science
Search
Sign In
Create Free Account
AZD2171
Known as:
AZD 2171
, AZD-2171
, AZD2171 Maleate
An indole ether quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, AZD2171 binds to and inhibits all three…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
AZD5438
Cediranib Maleate
Recentin
Broader (1)
cediranib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Abstract 2994: Cediranib affects tumor progression and survival of mice bearing patient derived ovarian carcinoma xenografts (EOC-PDX)
A. Decio
,
M. Cesca
,
Francesca Bizzaro
,
D. Belotti
,
R. Giavazzi
2014
Corpus ID: 72122160
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Vascular Endothelial Growth Factor (VEGFA/VEGFC) are over…
Expand
2010
2010
ABC-03: A randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers.
J. Valle
,
J. Bridgewater
,
M. Roughton
,
C. Dive
,
S. Hughes
,
H. Wasan
2010
Corpus ID: 74437572
TPS218 Background: The ABC-02 trial (Valle ASCO 2009, abstr. 4503), the largest ever randomized phase III trial in ABC to date…
Expand
2010
2010
Comparisons of the Efficacy of the Jak 1 / 2 Inhibitor AZD 1480 with the VEGF signaling inhibitor cediranib ( AZD 2171 ) and Sham Treatments in Mouse Tumors Using DCE-MRI , DW-MRI , and Histology
M. Loveless
,
D. Lawson
,
+7 authors
T. Yankeelov
2010
Corpus ID: 1821023
M. E. Loveless, D. Lawson, M. Collins, D. Morosini, C. Reimer, D. Huszar, J. Halliday, J. C. Waterton, J. C. Gore, and T. E…
Expand
2008
2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
S. Sridhar
,
M. Mackenzie
,
+8 authors
M. Moore
2008
Corpus ID: 78955136
5047 Background: Cediranib (AZD2171) is an oral highly potent, selective pan-VEGFR tyrosine kinase inhibitor expected to show…
Expand
2008
2008
Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer
U. Matulonis
,
S. Berlin
,
+7 authors
R. Penson
2008
Corpus ID: 74228979
5501 Background: Angiogenesis is important for ovarian cancer growth; blocking angiogenesis can lead to ovarian cancer regression…
Expand
2008
2008
Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib
M. Langenberg
,
C. Herpen
,
+7 authors
E. Voest
2008
Corpus ID: 78206272
3555 Background: Hypertension (HT) is a commonly reported side effect following administration of agents that target VEGF…
Expand
2008
2008
Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
T. Batchelor
,
G. Sorensen
,
+10 authors
R. Jain
2008
Corpus ID: 164272450
2007
2007
Effects of Ionizing Radiation on Normal and Tumor-Associated Lymphatic Vessels
J. D. Lobo
2007
Corpus ID: 18853074
Thesis (S.B.)--Massachusetts Institute of Technology, Dept. of Nuclear Science and Engineering, 2007.
2007
2007
Combined effects of targeting angiogenesis with bevacizumab and the VEGF signaling inhibitor AZD2171 in a xenograft model of human head and neck cancer
A. Bozec
,
F. Penault-Llorca
,
P. Formento
,
Clélia Dental
,
J. Fischel
,
G. Milano
2007
Corpus ID: 199625723
2120 Most anti-angiogenic agents target vascular endothelial growth factor-A (VEGF) or the VEGF receptor-2 (VEGFR-2). To…
Expand
2005
2005
Safety and tolerability of AZD2171, a highly potent VEGFR inhibitor, in patients with advanced prostate adenocarcinoma
C. Ryan
,
W. Stadler
,
B. Roth
,
T. Puchalski
,
M. Koehler
,
E. Small
2005
Corpus ID: 67929948
3049 Background: Vascular endothelial growth factor-A (VEGF) is a key factor involved in tumor blood vessel formation, and high…
Expand